Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CPG 10101
- Development stage
- Phase 2
- Lead developer
- Pfizer
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
CPG 10101 is a synthetic oligodeoxynucleotide (ODN) and a potent, selective unmethylated cytidine-phosphate-guanosine (CpG)-containing agonist of toll-like receptor 9 (TLR9). It has antiviral and immunomodulatory properties, designed to induce rapid and sustained immune responses with potential durable anti-viral effects. The drug was primarily developed for the treatment of chronic hepatitis C virus (HCV) infection, especially in patients who are refractory or non-responsive to standard therapies. Mechanistically, it stimulates TLR9 on immune cells, leading to induction of interferons and other cytokines that enhance antiviral immunity. Clinical studies have shown dose-dependent increases in markers of immune activation and reductions in HCV RNA levels[1][6][8].
- Brand names
- ACTILON
- Other names
- CpG ODN 10101
02
Targets
TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on CPG 10101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CPG 10101.